Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix

Jeong, Dae Hoon; Kim, Hyoung Kyu; Prince, Abd-EI Bary; Lee, Dae Sim; Kim, Young Nam; Han, Jing; Kim, Ki Tae

doi:10.3802/jgo.2008.19.3.173

Cited by 32 publications

(28 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The studies reported that some proteins or protein families are commonly reported as being differentially expressed regardless of species, in vivo or in vitro conditions, tissues and organs, and experimental objective. Interestingly, some of the proteins which we examined in this study such as afamin, ceruloplasmin and transferrin have also been reported by proteomic studies to be differentially expressed in patients with squamous cell carcinoma of the cervix, ovarian cancer, nasopharyngeal carcinoma and in those with central nervous system damage [23][24][25][26] .…”

Section: Discussionmentioning

confidence: 99%

Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11–13 Weeks?

Mastricci

Akolekar²,

Kuppusamy³

et al. 2011

Fetal Diagn Ther

View full text Add to dashboard Cite

Objective: The aim of this study is to identify potential biomarkers for fetal trisomy 21 from previous publications using proteomic techniques and examine the potential value of such biomarkers in early screening for this aneuploidy. Methods: This was a case-control study of 25 pregnancies with fetal trisomy 21 and 50 euploid controls undergoing first-trimester screening for aneuploidies by a combination of maternal age, fetal nuchal translucency (NT) thickness and maternal serum free β-human chorionic gonadotrophin (β-hCG) and pregnancy-associated plasma protein-A (PAPP-A). The maternal serum concentrations of afamin, apolipoprotein E, clusterin, ceruloplasmin, epidermal growth factor, fetuin-A, pigment epithelium-derived factor glycoprotein and transthyretin were determined using an ELISA and compared in the euploid and trisomy 21 groups. Results: In pregnancies with fetal trisomy 21, the median maternal age, fetal NT thickness and serum free β-hCG were increased, whereas serum PAPP-A was decreased. However, there were no significant differences between cases and controls in any of the biomarkers. Conclusion: Proteins identified as potential biomarkers for trisomy 21 using proteomic techniques have not been found to be useful in early screening for this aneuploidy.

show abstract

Section: Discussionmentioning

confidence: 99%

Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11–13 Weeks?

Mastricci

Akolekar²,

Kuppusamy³

et al. 2011

Fetal Diagn Ther

View full text Add to dashboard Cite

show abstract

“…Most of these studies, however, await evaluation by quantitative analyses using appropriate methods in sufficiently large study groups [26][27][28][29][30][31][32][33]. Of these many studies, two may highlight the importance of proper validation studies after a potential tumor marker candidate has been discovered [29,33].…”

Section: Clinical Applications Of Afamin Measurementmentioning

confidence: 99%

Afamin — A pleiotropic glycoprotein involved in various disease states

Dieplinger

2015

Clinica Chimica Acta

100

View full text Add to dashboard Cite

The human glycoprotein afamin was discovered as the fourth member of the albumin gene family. Despite intense research over the last 20 years, our knowledge of afamin's physiological or pathophysiological functions is still very limited. Circulating afamin is primarily of hepatic origin and abundant concentrations are found in plasma, cerebrospinal, ovarian follicular and seminal fluids. In vitro binding studies revealed specific binding properties for vitamin E. A previously performed analytical characterization and clinical evaluation study of an enzyme-linked immunosorbent assay for quantitative measurement of afamin in human plasma demonstrated that the afamin assay meets the quality specifications for laboratory medicine. Comparative proteomics has identified afamin as a potential biomarker for ovarian cancer and these findings were confirmed by quantitative immunoassay of afamin and validated in independent cohorts of patients with ovarian cancer. Afamin has also been investigated in other types of carcinoma. Most of these studies await further evaluation with validated quantitative afamin assays and require validation in larger patient cohorts. Transgenic mice overexpressing the human afamin gene revealed increased body weight and increased blood concentrations of lipids and glucose. These transgenic mouse data were in line with three large human population-based studies showing that afamin is strongly associated with the prevalence and development of the metabolic syndrome. This review summarizes and discusses the molecular, biochemical and analytical characterization of afamin as well as possible clinical applications of afamin measurement.

show abstract

“…The functions of afamin have been investigated in epidemiologic studies, most of which were cancerrelated. Circulating afamin concentrations have been studied in various types of carcinomas including ovarian (Jackson et al, 2007), bladder , colorectal (Choi et al, 2013), gastric (Humphries et al, 1844), uterine cervix (Jeong et al, 2008), breast (Opstal-van Winden et al, 2011, as well as thyroid cancer (Song et al, 2013). In addition, recently it was found that afamin was strongly associated with the prevalence and development of metabolic syndrome (Kronenberg et al, 2014).…”

Section: Introductionmentioning

confidence: 97%